Researchers will investigate a novel nanoparticle system to deliver chemotherapy drugs directly to osteosarcoma tumors, the most common bone cancer in dogs.
Researchers will conduct a clinical trial investigating the safety and anticancer effectiveness of trametinib, a drug to treat companion dogs with aggressive cancers.
Researchers will study metabolic irregularities associated with osteosarcoma that may contribute to disease progression, chemotherapy resistance and cancer spread.